Chikungunya Virus (CHIKV) Reagents

Investigate Chikungunya virus (CHIKV) entry, neutralization, and replication with a portfolio covering both structural and non-structural targets. CHIKV is a mosquito-borne alphavirus causing debilitating polyarthralgia, with expanding geographic range into previously unaffected regions. We offer recombinant antibodies targeting E2 spike glycoprotein and structural polyprotein (p130) with validated neutralization and FCM activity, an InVivoMAb functional-grade clone for in vivo protection studies, polyclonal antibodies and recombinant proteins covering E1, E2, Capsid, NSP1, NSP2, NSP3, and NSP4. RUO

Neutralizing & Structural Polyprotein AntibodiesRecombinant clones CHK152 and 9.8B with validated neutralization activity against CHIKV p130/structural polyprotein. The DC-series panel (DC1.370, DC1.380, DC1.415, DC1.55, DC1.56, DC2.550B, DC2.74, DC2.82, and others) provides FCM, IP, and BIF-validated clones for comprehensive epitope mapping and viral particle characterization.

E2 Spike Glycoprotein ReagentsRecombinant antibodies (CHK265, 5M16, 4J21, 5F10, C37) validated for ELISA, FCM, IF, and WB. Polyclonal antibody for IHC and WB. Recombinant E2 proteins in His-tag, Fc-tag, and multiple construct variants for immunoassay development and structural studies.

InVivoMAb & Anti-NSP2 NanobodyInVivoMAb clone m242 (anti-CHIKV VLP) validated for ELISA and neutralization — suitable for in vivo passive protection studies. Anti-NSP2 recombinant nanobody (Nb-A9) for intracellular detection of CHIKV replication complexes by ELISA.

Non-Structural Protein PanelMatched polyclonal antibody + His-tagged recombinant protein pairs for NSP1, NSP2, NSP3, and NSP4 — validated for ELISA, WB, and IHC. NSP2 also available as GST-His fusion. Complete non-structural protein coverage for replication complex studies and serodiagnostic antigen development.

All products manufactured by AtaGenix Laboratories under ISO 9001 & ISO 13485 quality systems.

References

1. Silva LA, Dermody TS. Chikungunya virus: epidemiology, replication, disease mechanisms, and prospective intervention strategies. J Clin Invest. 2017;127(3):737-749. DOI

2. Fox JM, Long F, Edeling MA, et al. Broadly neutralizing alphavirus antibodies bind an epitope on E2 and inhibit entry and egress. Cell. 2015;163(5):1095-1107. DOI